Open AccessThe value of interferon therapy for COVID-19 in children
Author(s) -
Л. Н. Мазанкова,
С. Г. Горбунов,
Э. Р. Самитова
Publication year - 2021
Publication title -
detskie infekcii
Language(s) - English
Resource type - Journals
eISSN - 2618-8139
pISSN - 2072-8107
DOI - 10.22627/2072-8107-2021-20-1-34-38
Subject(s) - covid-19 , interferon , medicine , coronavirus , virology , recombinant dna , immunology , first line , alpha interferon , intensive care medicine , biology , disease , infectious disease (medical specialty) , biochemistry , outbreak , gene
The article presents a literature review, which provides data on the role of interferons in the immunopathogenesis of COVID-19 and the clinical efficacy of drugs based on recombinant interferon-alpha 2b in the treatment of children with new coronavirus infection. Shown the leading role ofinterferons as factors of the first line of defense against various viruses, including SARS-CoV-2. Numerous studies have proven the feasibility of including interferon preparations in COVID-19 therapyregimens in children, both as combinations with antiviral agents and as monotherapy.